509 related articles for article (PubMed ID: 32085497)
1. Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets.
Fontana F; Raimondi M; Marzagalli M; Di Domizio A; Limonta P
Cells; 2020 Feb; 9(2):. PubMed ID: 32085497
[TBL] [Abstract][Full Text] [Related]
2. Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.
Kallifatidis G; Hoy JJ; Lokeshwar BL
Semin Cancer Biol; 2016 Oct; 40-41():160-169. PubMed ID: 27370570
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies.
Mokbel K; Wazir U; Mokbel K
Anticancer Res; 2019 Oct; 39(10):5231-5259. PubMed ID: 31570421
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets for green tea in prostate cancer prevention.
Adhami VM; Ahmad N; Mukhtar H
J Nutr; 2003 Jul; 133(7 Suppl):2417S-2424S. PubMed ID: 12840218
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.
Chhabra G; Singh CK; Ndiaye MA; Fedorowicz S; Molot A; Ahmad N
Cancer Lett; 2018 May; 422():9-18. PubMed ID: 29471004
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
8. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
9. Nanoformulation of natural products for prevention and therapy of prostate cancer.
Sanna V; Siddiqui IA; Sechi M; Mukhtar H
Cancer Lett; 2013 Jun; 334(1):142-51. PubMed ID: 23201598
[TBL] [Abstract][Full Text] [Related]
10. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
11. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer: the need for biomarkers and new therapeutic targets.
Felgueiras J; Silva JV; Fardilha M
J Zhejiang Univ Sci B; 2014 Jan; 15(1):16-42. PubMed ID: 24390742
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the molecular mechanisms and the potential chemopreventive/therapeutic properties of natural compounds in melanoma.
Fontana F; Raimondi M; Di Domizio A; Moretti RM; Montagnani Marelli M; Limonta P
Semin Cancer Biol; 2019 Dec; 59():266-282. PubMed ID: 31233829
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
16. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
17. Recent approaches in chemoprevention of prostate cancer.
Young CY
Curr Cancer Drug Targets; 2007 Nov; 7(7):681-8. PubMed ID: 18045073
[TBL] [Abstract][Full Text] [Related]
18. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
19. Recent progress on nutraceutical research in prostate cancer.
Li Y; Ahmad A; Kong D; Bao B; Sarkar FH
Cancer Metastasis Rev; 2014 Sep; 33(2-3):629-40. PubMed ID: 24375392
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
